SuperworthAgios Pharmaceuticals AGIO
- Market cap
- $2.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 22.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $98.3M
- +141% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −16.5%
Agios Pharmaceuticals trades at 22.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $98.3M over the last twelve months, up 141% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.4M+110% | $7.1M+65% | $8.2M+46% | $8.6M+28% | $9M+21% | $10.7M+51% | $8.7M+7% | $12.5M+45% | $12.9M+44% | $20M+86% | $20.7M+138% | $44.7M+259% | |
| Cost of revenue | $633K+22% | $586K+42% | $627K+13% | $1.5M+35% | $783K+24% | $1.3M+115% | $1.1M+73% | $1.7M+14% | $1.7M+114% | $1.9M+49% | $1.3M+22% | $3M+76% |
| Gross profit | $6.8M+126% | $6.5M+67% | $7.6M+50% | $7.1M+27% | $8.2M+21% | $9.5M+45% | $7.6M+1% | $10.8M+51% | $11.2M+37% | $18.1M+91% | $19.4M+154% | $41.7M+288% |
| R&D | $81.8M+26% | $77.5M+10% | $68.6M+2% | $77.4M+12% | $72.5M−12% | $82.8M+7% | $72.7M+6% | $91.9M+19% | $86.8M+20% | $88.1M+6% | $81.1M+12% | $100.8M+10% |
| SG&A | $25.8M−11% | $35.3M+8% | $31M+9% | $35.5M+17% | $38.5M+49% | $51.7M+46% | $41.5M+34% | $45.9M+29% | $41.3M+7% | $51.6M−0% | $48.3M+16% | $51.5M+12% |
| −$100.9M+11% | −$106.3M+7% | −$92.1M+2% | −$105.8M+13% | −$102.8M+2% | −$125M+18% | −$106.6M+16% | −$127.1M+20% | −$116.9M+14% | −$121.6M−3% | −$110M+3% | −$110.6M−13% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$91.3M | −$95.9M | n/a | n/a | $1B | −$105.4M+10% | n/a | n/a | −$103.4M | −$109.1M+4% | n/a | n/a |
| $0 | $0 | n/a | n/a | $53.1M | −$8.9M | n/a | n/a | $0 | −$1M−89% | n/a | n/a | |
| Net income | −$91.3M+12% | −$95.9M | −$81.5M+1% | −$96.1M+15% | $947.9M | −$96.5M+1% | −$89.3M+10% | −$112M+17% | −$103.4M | −$108M+12% | −$99.1M+11% | −$100.7M−10% |
| −$1.64+10% | −$1.72 | −$1.45−1% | −$1.69+12% | $16.22 | −$1.69−2% | −$1.55+7% | −$1.93+14% | −$1.78 | −$1.85+10% | −$1.69+9% | −$1.69−12% | |
| 55.8M+2% | 55.9M+2% | 56.4M+2% | 56.8M+2% | 58.4M+5% | 57.1M+2% | 57.5M+2% | 57.9M+2% | 58.1M−1% | 58.3M+2% | 58.8M+2% | 59.5M+3% |
Revenue: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Gross profit: 36 periods, Q3 FY17 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
SG&A: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Income tax: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY12 and Q1 FY13: 6 months less the 3 months printed beside them.
EPS, diluted: 16 periods, Q1 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY12: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Agios Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AGIOAgios Pharmaceuticals | $2.2B | n/m | n/a | 22.5× | +141% | n/m | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $2.2B | 15.7× | 37.5× | 2.0× | +17% | 11.1% |
More on Agios Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 341Healthcare stocks with the fastest revenue growth
- #6of 97Large drugmakers with the fastest revenue growth
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .